Recently, Yankova et al. 135 reported that STM2457, a specific METTL3 inhibitor, could be used as a promising therapeutic drug for AML, which is expected to enter clinical trials as the first epigenetic inhibitor drug. The gene discussed is METTL3; the disease is acute myeloid leukemia.